Molecule intelOpportunity: Moderate0Underserved

Human Insulin Regular

8 brands · 2 companies · product forms

Opportunity snapshot

Launch attractiveness
44
Market saturation
6
Price room
43
Regulatory risk
0
8
brands
2
companies
Rs 2,192.51
median price
9
price points
2.72x
price spread
90
confidence %

Who competes here

Top companies by brand count — concentrated market · leader share 75%

Price room

Across observed sources and strengths
CheapestRs 1,000.32
MedianRs 2,192.51
Most expensiveRs 2,719.08
Spread2.72×
Sources: DRAP-official, DVAGO, Servaid

max/min price ratio 2.72x across 9 trusted points (Rs 1000.32-2719.08). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Brands & products on the market

Sample of 1 live product for Human Insulin Regular — each links to its own medicine page.

Why this score

Launch attractiveness

40% supply-gap(40) + 25% price-variation(43) + 20% low-competition(94) + 15% supply-disruption(0), damped by confidence(90). Higher = more attractive, less crowded opportunity.

Market saturation

2 canonical companies and 8 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

max/min price ratio 2.72x across 9 trusted points (Rs 1000.32-2719.08). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory risk

No DRAP alerts on this molecule's brands.

Confidence

Reduced by: no ATC code.

Packaged brief for this moderate opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.